

19 September 2017

**Oncimmune Holdings plc
("Oncimmune" or the "Company")**

First Distribution Agreements Signed for *EarlyCDT*[®]-Lung Kit in Europe

Exclusive agreements for Denmark, Norway and Sweden with aggregate minimum sales commitment of approximately £500,000

Nottingham, UK – 19 September 2017: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary *EarlyCDT*[®] platform technology, today announces it has signed three new exclusive distribution agreements for its *EarlyCDT*[®]-Lung test with LabLab ApS, Diuvita Diagnostics AS and XboXLab AB in Denmark, Norway and Sweden respectively.

The agreements allow for the sale of the CE marked kit to local laboratories and as a central laboratory test. The three agreements are for an initial term of three years and include minimum sales commitments of approximately £500,000. First sales are expected to commence late in 2017/early 2018.

Geoffrey Hamilton-Fairley, CEO of Oncimmune, commented: "These distribution agreements, which we anticipate to be the first of many across Europe, give us full coverage of the Scandinavian region where we have received a great deal of interest in our *EarlyCDT*[®]-Lung test. As part of the strategy indicated at the time of our IPO, we outlined our plan to grow into multiple regions with multiple products and these latest agreements not only show our commitment to that strategy but also indicate the strength and potential of our *EarlyCDT*[®]-Lung test and kit."

For further information:

Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk

Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary *EarlyCDT*[®] platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, *EarlyCDT*[®]-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been



sold. **EarlyCDT®-Lung** is available through physicians in the US and also privately in the UK and other regions. **EarlyCDT®-Lung** is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers. The NHS Scotland ECLS study of over 12,000 high-risk smokers is now fully recruited and in the final follow up stage. **EarlyCDT®** tests for liver and ovarian cancer are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker **ONC.L**. For more information visit www.oncimmune.com